By Stan Choe and Damian J. Troise

Updated 4:35 pm ET

Wall Street rallied Monday as hopes for economic aid from Washington helped it recover all its knee-jerk losses after learning President Donald Trump tested positive for the coronavirus.

The S&P 500 jumped 60.16 points, or 1.8 percent, to 3,408.60 amid widespread gains, with nine out of 10 stocks in the index rising. Energy producers and tech companies led the way.

Treasury yields, stocks overseas and oil all climbed after Trump and House Speaker Nancy Pelosi both noted the importance over the weekend of additional support for the economy. The market's rally accelerated after Trump tweeted in the afternoon that he'll leave the hospital, though his medical team said he "may not entirely be out of the woods yet."

The Dow Jones Industrial Average rose 465.83 points, or 1.7 percent, to 28,148.64, and the Nasdaq composite climbed 257.47, or 2.3 percent, to 11,332.49. Smaller stocks rose even more in an indication of improved market optimism, and the Russell 2000 index jumped 42.67, or 2.8 percent, to 1,581.96.

The lift follows through on a comeback that helped markets cut their losses on Friday, after Trump's condition became publicized. Stocks initially tumbled as the jolt of uncertainty raised concerns that a White House victory for Democrat Joe Biden would mean higher taxes and tighter regulations for companies, which could drag down their profits. But analysts said a Democratic sweep of the election could also raise the probability of a big government support plan for the economy, something that investors have been clamoring for since jobless benefits and other stimulus Congress approved in March expired.

The market's moves on Monday and late Friday suggest investors are anticipating either a large stimulus effort or the increased likelihood of a "blue wave," said Yousef Abbasi, global market strategist at StoneX.

Stocks got an immediate lift Friday afternoon after Pelosi told airline executives to stop the furloughs of tens of thousands of workers because aid for the industry was "imminent," either as a stand-alone effort or as part of a wider rescue package. A stand-alone bill for airlines failed to advance in the House on Friday, but hopes remain for a larger effort.

Over the weekend, Trump tweeted from the hospital that the country wants and needs more economic stimulus. "Work together and get it done," he said on Saturday.

A day later, Pelosi said that the two sides are making progress, but they still haven't reached a breakthrough. "It just depends on if they understand what we have to do to crush the virus," she said in an interview on CBS.

A report on Monday said growth for the nation's services industries last month was stronger than economists expected. It's an encouraging piece of data, but it follows a string of mixed reports that have shown some areas of the economy slowing since Congress' last round of aid expired.

"Our dark expectations in the aftermath of the COVID-19 crisis are not coming through," said Scott Knapp, chief market strategist at CUNA Mutual Group. "The pace of the improvement is slowing, but it's still upward."

He expects the upcoming election to throw some more volatility into the markets, but not much as investors seem somewhat indifferent to the potential outcome. He said a key signal to that indifference was the market's muted response to the news that Trump had contracted COVID-19.

"It's pretty difficult to overstate how understated the market's reaction was," Knapp said.

Shares of Regeneron rose 7.1 percent after Trump received an experimental drug from the company that supplies antibodies to help the immune system fight the virus.

Trump on Friday also began a five-day course of remdesivir, a Gilead Sciences drug currently used for moderately and severely ill patients. The drugs work in different ways — the antibodies help the immune system rid the body of the virus, and remdesivir curbs its ability to multiply.

Gilead rose 2.3 percent.

MyoKardia, a biopharmaceutical company, surged 57.8 percent after Bristol Myers Squibb said it would buy the 8-year-old company for $13.1 billion, or $225 per share in cash.

On the losing side was DraftKings, which fell 5.1 percent. It and some of its existing investors are selling 32 million shares of the company's stock after it nearly sextupled in 2020.

In Asian trading, Japan's Nikkei 225 gained 1.2 percent, South Korea's Kospi jumped 1.3 percent and Hong Kong's Hang Seng rose 1.3 percent.

Fujitsu President Takahito Tokita apologized Monday for the breakdown last week in the Tokyo Stock Exchange's trading system, which the Japanese company had developed. Speaking during an online webinar, he promised to work with the exchange to prevent a recurrence of the malfunction in Fujitsu's Arrowhead system, which caused all trading to be halted in Tokyo on Oct. 1.

By Friday, trading resumed after the problem was fixed.

In Europe, Germany's DAX returned 1.1 percent, and France's CAC 40 rose 1 percent. The FTSE 100 in London added 0.7 percent.

The yield on the 10-year Treasury rose to 0.76 percent from 0.70 percent late Friday.

___

AP Business Writer Yuri Kageyama contributed.

Share:
More In Business
TC BioPharm Goes Public, Looks to Future of Cancer, COVID-19 Cell Therapies
TC BioPharm, a biopharmaceutical company focused on developing cell therapy products targeting, went public on the Nasdaq in January. CEO Bryan Kobel joined Cheddar to talk about the company's IPO launch, its cancer-fighting therapeutics tech, and its potential for using its research to treat COVID-19. "The opportunity here for us is to really get safety data and covid and expand into other areas," Kobel said. "So from COVID, where we hope to treat patients, hopefully maybe the elderly population, populations that that really can't handle the antivirals because they're too hard in the system, well then we'll expand out into maybe severe influenza Ebola, other viral and viral infections where we think we can be helpful."
A Closer Look at the Gaming Sector and its Future in the Metaverse
The gaming industry has been under the spotlight so far this year following some big mergers and acquisitions. This week featured earnings of three major gaming companies, but also Meta and for the latter, things are not doing too hot. Joining Cheddar News to break it all down was Kenny Rosenblatt, President and Co-Founder of Arkadium.
Economy Appears to Be Back on Track in 2022 With Job Growth
Following the surprising big beat on estimates for the January jobs report, William M. Rodgers III, vice president and director of the Institute for Economic Equity at the Federal Reserve Bank of St. Louis, joined Cheddar News to break down the data. “We ended 2021 with a strong crescendo to a recovery that had taken hold, and we started 2022 in good fashion." He also discussed the dueling pressures of wage growth and inflation.
Amazon Strong Growth Attributed to the Cloud Despite Retail Headwinds
While it was a volatile week in tech as Meta experienced the biggest one-day drop in the history of the U.S. stock market, industry giant Amazon reported 40 percent growth — largely on the strength of the cloud. Dan Ives, managing director of equity research at Wedbush Securities, joined Cheddar News to break down how the e-commerce company stock managed to pop despite headwinds against its core retail business. "It's all about cloud because of sum of the parts, you could argue, amazon could be $3,500/$4,000 stock just based on cloud," he said. Ives also addressed the apparent the differing impact of Apple iOS changes on Facebook and Snapchat.
Investors May Be Wary of Ford Due to Ongoing Supply Chain Issues
Following Ford's earnings miss, the stock price dropped despite a bullish outlook from the auto giant. Karl Brauer, an executive analyst with ISeeCars.com, joined Cheddar to break down why investors may not be sold on the carmaker because of the ongoing factor of supply constraints. "The product is not an issue. There's really good product coming from them, including the electric vehicle side, and the demand is not an issue. There's plenty of demand, but nobody really has a solid grasp on when we're going to get past the supply chain issue," said Brauer.
Load More